Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)

NCT04043455 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

273

Enrollment

INDUSTRY

Sponsor class

Stopped Business Decision

Conditions

Irritable Bowel Syndrome

Interventions

DRUG: Olorinab
DRUG: Olorinab
DRUG: Olorinab
DRUG: Placebo
DRUG: Olorinab
DRUG: Olorinab

Sponsor

Arena Pharmaceuticals